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Increasing resistance of Pseudomonas aeruginosa (P. aeruginosa) to conventional treatments demands the search for novel
therapeutic strategies. In this study, the antimicrobial activity of dehydroleucodine (DhL), a sesquiterpene lactone obtained
from Artemisia (A.) douglasiana, was screened against several pathogenic virulence effectors of P. aeruginosa. In vitro, minimum
inhibitory concentration of DhL was determined against P. aeruginosa strains PAO1, PA103, PA14, and multidrug resistant clinical
strain, CDN118. Results showed that DhL was active against each strain where PAO1 and PA103 showed higher susceptibility (MIC
0.48mg/mL) as compared to PA14 (MIC 0.96mg/mL) and CDN118 (MIC 0.98mg/mL). Also, when PAO1 strain was grown in
the presence of DhL (MIC
50
, 0.12mg/mL), a delay in the generation time was noticed along with significant inhibition of secretory
protease and elastase activities, interruption in biofilm attachment phase in a stationary culture, and a significant decline in Type III
effector ExoS. AtMIC
50
, DhL treatment increased the sensitivity ofP. aeruginosa towards potent antibiotics. Furthermore, treatment
of P. aeruginosa with DhL prevented toxin-induced apoptosis in macrophages. These observations suggest that DhL activity was
at the bacterial transcriptional level. Hence, antimicrobial activity of DhL may serve as leads in the development of new anti-
Pseudomonas pharmaceuticals.
1. Introduction
Pseudomonas aeruginosa (P. aeruginosa) is a Gram-negative
opportunistic pathogen with a high prominence of intrinsic
antibiotic resistance [1]. Resistant strains of P. aeruginosa
are commonly found as a secondary infection in immune-
compromised patients with cystic fibrosis, COPD, AIDS,
and cancer and even among diabetics [2–4], leaving seri-
ous blood stream infection with significant mortality and
healthcare costs [5]. The success in establishing P. aeruginosa
pathogenicity is largely due to formation of intractable
biofilm and secretion of myriads of virulent factors including
LasA protease, LasB elastase, pyocyanin, pyoverdin, Type III
secretion (T3S) effectors, and alginate [6–9]. Unfortunately,
selection of the most appropriate antibiotic is complicated
due to the ability of P. aeruginosa to develop resistance to
multiple classes of antibiotics.
P. aeruginosa can develop resistance to antibiotics because
of the low permeability of its outer membrane, the con-
stitutive expression of various efflux pumps [10], and the
naturally occurring chromosomal AmpC 𝛽-lactamase, turn-
ing it resistant toward penicillin G, aminopenicillins, and
first- and second-generation cephalosporin [11]. P. aeruginosa
easily acquires additional resistancemechanisms,which leads
to serious therapeutic problems [12]. Currently, antipseu-
domonas treatments include higher-than-usual doses of 𝛽-
lactam, fluoroquinolones, and amino glycosides, which pos-
sess a high degree of toxicity and very low eradication rate
[13].The dearth of successful antibiotics to completely control
P. aeruginosa infectionmakes it crucial to finding alternatives
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to currently available drugs. Since the pathogenicity of P.
aeruginosa is regulated by several secretory-systemsmediated
cell-to-cell communications, inhibition of this system can
cause attenuation of virulence and protect against infection
[14, 15].
Artemisia, the largest diverse genera of Asteraceae family,
possesses medicinally valuable essential oils and secondary
metabolites [16, 17]. Many studies indicate antimicrobial
activity in Artemisia (A.) spp. [18–20]. A. douglasiana is well
documented as preventive folk medicine in Argentina [21].
Dehydroleucodine (DhL), a sesquiterpene lactone of the gua-
ianolide group, is one of the principal active secondary met-
abolites in A. douglasiana [21]. DhL, first isolated from Lid-
beckia pectinata [22], possesses cytoprotective activity [23] as
well as antimicrobial activity against several pathogens [24–
27].
In this study, we tested the antibacterial activity of DhL
and against P. aeruginosa virulence. At first we evaluated the
minimum inhibitory concentration (MIC) and its synergistic
effect on other commercial antibiotics, and thenwe examined
the antipseudomonal properties of this phytochemical in
terms of arresting growth and attenuating virulent factors
such as biofilm formation and secretion of Type III effectors,
elastase A, and elastase B. We also assessed the capacity of
this phytocompound to inhibitP. aeruginosa induced host cell
toxicity.
2. Material and Methods
2.1. Reagents. Dehydroleucodine was extracted from A. dou-
glasiana (Voucher specimen 2012-1018-F, Fairchild Tropical
Botanical Garden, Miami, FL) as previously documented
[21, 28]. DH-DhL was prepared as described previously [21].
All chemicals and reagents were purchased from Sigma-
Aldrich (St. Louis, MO), unless otherwise indicated. Primary
and secondary antibodies used in immunoblotting were
purchased from Cell Signaling Technology Inc. (Danvers,
MA). Culture supplies were purchased from Invitrogen Life
Technologies (Carlsbad, CA). Prototypic P. aeruginosa strains
used in this study are PAO1, clinical isolates PA103 and PA14
(kindly provided by Dr. Dara Frank, University ofWisconsin,
Madison), and P. aeruginosa strain PA103ΔUΔT, expressing
pUCP plasmid-encoded ExoS tagged with a hemagglutinin
epitope (ExoS-HA) (kindly provided by Dr. Joan C. Olson,
West Virginia University). In addition, Staphylococcus aureus
(ATCC 12600) was used in the LasA assay. Cells were
maintained in Luria Broth (LB) (Life Technologies, Carlsbad,
CA) or Agrobacterium (AB) minimum medium (Bio-World,
Visalia, CA) to which glucose and casein amino acids [20%,
wt/vol] were added.
2.2. Determination of Minimum Inhibitory Concentration
(MIC) andMinimumBactericidal Concentration (MBC). The
minimum inhibitory concentration of DhL was determined
by micro dilution broth assay [12] for PA01, PA103, PA14, and
CDN118 strains of P. aeruginosa. Serial doubling dilution of
DhL was made, ranging from 2.24mg/mL to 0.224𝜇g/mL.
Twenty (20) 𝜇L of standard inoculums (0.5 McFarland) of all
three P. aeruginosa strains was introduced to desired volume
of growth medium and incubated at 37∘C for 18 hr. Controls
were set up as follows: (1) sterility control: LB broth only; (2)
growth control (negative): LB broth + bacteria; (3) positive
control: LB broth with Gentamycin; (4) vehicle control: LB
broth + bacteria + DMSO. MIC was interpreted as the least
concentration with no observable turbidity. Optical density
readings (𝜆 = 600 nm) were taken using microplate reader
at 0 and 18 hr. MIC
90
and MIC
50
were determined as the
concentration of DhL that inhibited bacterial growth by 90%
and 50%, respectively. Results were reported as the MIC,
MIC
50
, and MIC
90
for growth at 18 hr after inoculation.
Minimum bactericidal concentration (MBC) was
recorded as a lowest extract concentration killing 99.9%of the
bacterial inocula after 24 h incubation at 37∘C. Each experi-
ment was repeated at least three times. MBC values were
determined by removing 100 𝜇L of bacterial suspension from
subculture demonstrating no visible growth and inoculating
nutrient agar plates. Plates were incubated at 37∘C for a total
period of 24 h. The MBC is determined with the wells whose
the concentrations are ≥ MIC [29]. According to the ratio
MBC/MIC, we appreciated antibacterial activity. If the ratio
MBC/MIC is 1 or 2, the effect was considered bactericidal
but if the ratio MBC/MIC is 4 or 16, the effect was defined as
bacteriostatic [30].
For each assay 0.12mg/mL (MIC
50
) of DhL was added
to P. aeruginosa culture at early log phase unless otherwise
stated. The effect of DhL on bacterial cell proliferation was
determined by monitoring the growth curve of P. aeruginosa
strain PAO1. Briefly, an overnight culture (in LB medium) of
PAO1was diluted toOD
600
0.05 in LBmedium (control) or LB
and DhL (0.12mg/mL) and incubated at 37∘C while shaking.
The OD
600
was monitored at 30min intervals until OD
600
of approximately 1.7 was obtained (approximately 8 hr). All
OD
600
measurements were verified at a 1/10 dilution for
greater accuracy.
2.3. Determination of Antibiotic Synergy with DhL by the
E-Test Strip. Bacterial suspensions (PAO1) homogenized in
sterile saline were prepared from overnight fresh cultures
to a McFarland standard of 0.5 and were spread with a
sterile cotton swab on 150mm Mueller-Hinton agar control
and containing DhL (MIC
50
) plates. The agar plates were
allowed to stand for 15–20min at room temperature to
allow any excess surface moisture to be absorbed before
placement of MIC test strips. Antibiotic gradient strips (E-
test, Liofilchem, Italy) containingGentamycin (concentration
range 0.016–256mg/L), Ciprofloxacin (concentration range
0.002–32mg/L), or Chloramphenicol (concentration range
0.016–256mg/L) were then used; the MHA plates with the
over layered strips were incubated at 37∘C or 24 hr, and the
growth inhibition zones were measured. Differences in MIC
values between the control and test plates were recorded
(end points were determined according to themanufacturer’s
instructions).
The Muller Hinton agar (MHA) dilution method was
used to evaluate the Fractional Inhibitory Concentration
Index (FICI) of DhL with Chloramphenicol on PAO1 being
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tested following previously established protocol [31, 32].
Eight serial twofold dilutions of DhL were prepared as
described before, to obtain final concentration range of
2.24mg/mL–0.224𝜇g/mL. A series of twofold serial dilutions
of Chloramphenicol was also prepared similar to DhL.
All antibacterial standards dilutions were mixed with the
appropriate concentration of DhL compounds thus obtaining
a series of the combinations of Chloramphenicol and DhL.
The concentrations prepared corresponded to 1, 1/2, 1/4, 1/8,
1/16, 1/32, 1/64, 1/128, and 1/256 of MIC values. The 96-well
plate containing 100 𝜇L of Mueller Hinton (MH) broth was
used. For bacteria strain PAO1, three columns of eight wells
of 96-well plate were used. Each well received the culture
medium + combination of DhL with Chloramphenicol +
inoculum (10𝜇L of inocula) and INT (sigma-Aldrich, St.
Louis, MO) (50𝜇L; 0.2mg/mL). The plates were covered
and incubated at 37∘C for 24 hr. All tests were performed
in triplicate and the bacterial activity was expressed as the
mean of inhibitions produced. Inhibition of bacterial growth
was judged by rose or yellow color. The analysis of the
combination of DhL and Chloramphenicol was obtained by
calculating the Fractional Inhibitory Concentration Index
(FICI) as follows: FICI = (MICof the combination ofDhL and
Chloramphenicol/MICa alone) + (MIC of the combination
of DhL and Chloramphenicol/MICb alone), where MICa
is Minimal Inhibitory Concentration of DhL and MICb is
Minimal Inhibitory Concentration Chloramphenicol. The
FICI was interpreted as follows: (1) a synergistic effect when
FICI ≤ 0.5; (2) an additive or indifferent effect when FICI >
0.5 and <1; and (3) an antagonistic effect when FICI > 1.
2.4. LasA and LasB Activities. Staphylolytic activity of LasA
was determined spectrophotometrically by measuring the
decrease in absorbance at 595 nm (OD
595
) due to lysis
of heat inactivated Staphylococcus aureus (S. aureus) cells
(0.3mg/mL; 0.02MTris-HCl, pH 8.5) upon addition of PAO1
culture supernatants [34]. One hundred (100)𝜇L aliquot of
P. aeruginosa culture supernatant with or without DhL (after
normalizing the supernatant total protein concentration)
was added to 900 𝜇L of a boiled S. aureus suspension. The
OD
595
was determined after 0, 5, 10, 20, 30, 45, and 60min,
respectively. Activity was expressed as the change in the
OD
595
/hr/𝜇g protein. One unit of activity was defined as the
amount of enzyme that causesOD
595
decrease of 1 absorbance
unit/min.
Elastolytic activity of LasB in PAO1 culture fluids was
determined by elastin Congo red (ECR) assay [35]. One hun-
dred (100) 𝜇L aliquot of the ABmedium culture supernatants
frommid log phase with or without DhL treatment (concen-
tration was normalized) was added to 900 𝜇L of ECR buffer
(100mM Tris-HCl, 1mM CaCl
2
, pH 7.5) containing 20mg
ECR. Tubes were incubated for 18 hr at 37∘C with rotation
and then were placed on ice after 0.1mL of 0.12M EDTA was
added. Insoluble ECRwas removed by centrifugation, and the
OD
495
was measured. Absorption due to pigments produced
by P. aeruginosawas corrected for by subtracting theOD
495
of
each sample that had been incubated in the absence of ECR.
Cell-free AB medium alone and AB medium with DhL were
used as negative controls.
2.5. Relative Gene Expression Analysis of LasR. Total mRNA
was purified from mid log phase PAO1 (108 cells/mL)
untreated or after DhL treatment using QIAGEN RNeasy
mini kit (QIAGEN, Valencia, CA) and quantified following
standard techniques. cDNA was synthesized from 1 𝜇g of
mRNA using iScript Supermix (Biorad, Hercules, CA). Real
time PCRwas performed in triplicate from each sample using
a BioradCFx96Real Time System (Biorad,Hercules, CA) and
SsoAdvanced SYBR Green Supermix (Biorad, Hercules, CA)
with the primers for LasR (5󸀠-GAAATGTGCCTTTCCGGC-
ACAAC-3󸀠 and 5󸀠-AGGCCATAGCGCTACGTTCTTCTT-
3󸀠) and gyrB (DNA-gyrase subunit B: 5󸀠-TGCTGAAGG-
GGCTGGATGCCGTACGCAAGC-3󸀠 and 5󸀠-TATCCA-
CCGGAATACCGCGTCCATTGTCGC-3󸀠). Relative gene
expression was determined using the 2−ΔΔCT method [36].
Mean CT of triplicate measures was computed for each
sample. Sample mean CT of gyrB (internal control) was
subtracted from the sample mean CT of the respective gene
of interest (ΔCT). The ΔCT of the sample with no treatment
was selected calibrator and subtracted from the mean ΔCT of
each experimental sample (ΔΔCT). 2
−ΔΔCT yields fold change
in gene expression of the gene of interest normalized to the
internal control gene expression.
2.6. Polyvinyl Chloride Biofilm Formation. The effect of DhL
on the attachment phase of biofilm formation was measured
by using the polyvinyl chloride biofilm formation assay [37].
Briefly, overnight cultures of PAO1 were resuspended in fresh
ABmedium in the presence and the absence DhL. After 24 hr
of incubation at 30∘C, the biofilms in the polyvinyl chloride
microtiter plates were visualized by staining with a crystal
violet solution. Plates were rinsed once to remove planktonic
cells, and then attached cells to the surface were quantified by
solubilizing the dye in ethanol by measuring the absorbance
at OD
546
.
2.7. Type III Secretion Assays. Low calcium fractionation
protocol was adopted for the detection of Type III secre-
tion effectors [8]. Briefly, P. aeruginosa PAO1, PA103ΔUΔT
(control), and PA103ΔUΔT expressing HA-ExoS were grown
overnight in LB. Bacteria were then subcultured 1 : 1,000 in
LB supplemented with 5mM EGTA with or without DhL
and grown for 6 h at 37∘C with aeration. Bacterial densities
were determined at OD
600
. Bacteria were sedimented by
centrifugation at 3,220×g for 15min at 4∘C.
Culture supernatant was collected, and proteins were
precipitated with 5% trichloroacetic acid and washed once
with ice-cold acetone. Proteins were resuspended according
to culture density and separated by SDS-PAGE. Proteins
derived from precipitated PAO1 supernatant were run on
SDS-PAGE and then either stained with Coomassie blue
or transferred onto nitrocellulose membranes as described
below.
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2.8. Immunoblotting Analysis. Samples (treated and non-
treated with DhL) were resuspended in sample buffer and
then separated by SDS-PAGE, transferred onto nitrocellu-
lose membranes (Biorad Laboratories, Hercules, CA, USA),
and incubated with antibodies specific to HA-epitope tag
for 2 hr at room temperature. Subsequently, membranes
were incubated with the appropriate horseradish peroxidase-
conjugated secondary antibodies. A Super Signal West Pico
chemiluminescent substrate kit (Pierce/Thermo Fisher Sci-
entific, Inc., Rockford) was used to visualize protein bands.
Band densities fromWestern blots were quantified using the
Image J64 software at a gray-scale amplification of 600 dpi.
2.9. P. aeruginosa Mediated Apoptosis of Macrophage Cells.
The effect of DhL treatment on P. aeruginosamediated apop-
tosis of J774-Eclone mouse macrophage cell was monitored
as previously described [38]. J774-Eclone cell monolayer was
plated from suspension culture 1 day prior to infection in
DMEM supplemented with 5% FBS (DMEM-5%FBS). Cell
monolayer (5 × 105 cells per well; >80% confluence) was
washed with phosphate-buffered saline (PBS), mixed with
either DhL treated or DhL-untreated PAO1 bacteria at a
multiplicity of infection (MOI) of 20 and incubated for
2 hr at 37∘C in a 5% CO
2
incubator. The cells were washed
with PBS to remove the nonadhering bacteria. Fresh DMEM
containing 5% FBS was supplemented with 400𝜇g/mL of
Gentamycin and then added to cells for an additional 2 hr
to kill any unwashed P. aeruginosa. As positive control for
the apoptosis, J774-Eclone cells were incubated with 0.1 𝜇M
of Staurosporine (Fischer Scientific, Waltham, MA) for 1 hr.
Cells were washed once with PBS and stained with 1mg/mL
Hoechst 33258 (Molecular Probes, Inc., Eugene, OR) for
10min in the dark as described in Section 2. Chromatin
condensation was examined under the fluorescence micro-
scope by using a DAPI (4, 6-diamidino-2-phenylindole) filter
after stained cells were mounted onto slides using mounting
medium.
2.10. Statistical Analysis. All experiments were performed
independently in triplicate and each experiment was repeated
three times. Values represent the mean ± SEM of three
independent experiments. Data were analyzed by Mann-
Whitney U test with a significance threshold value of 0.05,
by using the SPSS (Chicago, IL) statistical software package.
3. Results
We first examined the antibacterial effects of DhL against
several P. aeruginosa strains (PAO1, PA103, PA14, and clinical
strain CDN118, a multidrug resistant strain) with vary-
ing concentrations of DhL ranging from 2.24mg/mL to
0.224mg/mL. As displayed in Table 1, DhL inhibited 50%
of PAO1 and PA103 population at 0.12mg/mL whereas
0.48mg/mL of DhL successfully inhibited 50% of PA14
population. The minimum inhibitory concentration that is
the lowest concentration of the DhL solution required to
completely inhibit the growth of the P. aeruginosa was
0.48mg/mL for PAO1 and PA103 as compared to 0.96mg/mL
Table 1: Minimum inhibitory concentration against P. aeruginosa
strains was carried out previously [33]∗. It shows complete killing
(MIC)∗, 50% of killing (MIC
50
)∗, and 90% of killing (MIC
90
)∗.
P. aeruginosa
strain Antimicrobial agent
MIC MIC
90
MIC
50
(mg/mL) (mg/mL) (mg/mL)
PAO1 DhL 0.48 0.24 0.12
Gentamycin 0.075 0.064∗ 0.032∗
PA14 DhL 0.96 0.48 0.24
Gentamycin 0.1 >0.064∗ >0.032∗
PA103 DhL 0.48 0.24 0.12
Gentamycin 0.075 0.064∗ 0.032∗
CDN118 DhL 0.98 0.56 0.28
Gentamycin 0.1 >0.064∗ >0.032∗
Table 2: Bacteriocidal (+) and bacteriostatic (−) effect of DhL on
several experimental strains of Pseudomonas aeruginosa.
Pseudomonas
aeruginosa strains Bacteriocidal (+) Bacteriostatic (−)
PAO1 +
PA103 +
PA14 −
Clinical strain −
Bacteriocidal (MBC/MIC = 1 or 2).
Bacteriostatic (MBC/MIC = 4 or 16).
Results are means of number of colonies ± standard deviation.
for the more virulent strain PA14 (Table 1). However, for
the clinical strain DhL MIC was 0.28mg/mL (Table 1). The
bactericidal and bacteriostatic effect of DhL was determined
by MBC/MIC (Table 2). The antimicrobial effect of DhL is
prominent against all strains of P. aeruginosa tested here,
although strains PAO1 and PA103 seemed to be more suscep-
tible to DhL than PA14 and clinical strain CDN118.
We then determined whether DhL activity at MIC
50
concentrationwas effective to slow down the bacterial growth
in vitro in a time-dependent manner. We found that the ideal
growth phases of PAO1 represented a log phase during the
first 150min and then a stationary phase with OD
600
1.7 that
remained until 360min (Figure 1). Treatment with DhL at
MIC
50
concentration (0.12mg/mL) declined the slope of log
phase that ended at 270min of culture, which then turned
to stationary phase at a very low OD
600
(i.e., 0.7). Noticeable
difference in generation time (50±5%)was observed between
1 and 3 hr of growth (mid log phase) between treated and
untreated PAO1 (Figure 1). Treatment at MIC
90
failed to
portray normal growth curve (data not shown).
Several studies have suggested that combining plant- or
animal-derived natural compounds with antibiotics is a new
strategy for developing therapies against infections [39–41].
We report that the antimicrobial activities of commercial
antibiotics are enhanced by pretreating P. aeruginosa with
0.12mg/mLDhL.MICvalueswere decreased by the coactions
of DhL with gentamicin (aminoglycoside), Chloramphenicol
and Ciprofloxacin (fluoroquinolone), Figure 2. To further
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Figure 1: DhL inhibits growth of P. aeruginosa. (a) Chemical structure of DhL. (b) P. aeruginosa PAO1 strain was grown in the absence (I) and
presence (e) of 0.12mg/mL DhL from early log phase to stationary phase (1.7 hr) at 37∘C with constant shaking. Generation time (between
1 and 3 hr) of PAO1 in presence of DhL (calculated from three independent experiments) was 64 ± 5min whereas it was 35 ± 5min in the
control PAO1 culture. Data represent the mean of three independent experiments ± SEM.
Treatment Gentamycin Chloramphenicol Ciprofloxacin
Control 1.0 1.0 0.125
DhL
0.38 0.38 0.064MIC50: 120 (𝜇g/mL)
MIC (𝜇g/mL)
(a)
1.0
(b)
0.38
(c)
Figure 2: Synergistic effect of DhL with systemic antibiotics. (a) Table represents synergistic activity of subinhibitory concentration of DhL
and antibiotics belonging to various classes determined by the E-test strip/agar dilution method against PAO1. (b) A control plate (MHA)
with Chloramphenicol E strip. (c) A Chloramphenicol E-test plate (MHA) with DhL at a dilution of MIC
50
concentration.
confirm the combined effect of DhL and conventional antibi-
otics we calculated the FICI for DhL and Chloramphenicol
combination on PAO1 (Table 3). Overall the observations
from both assays demonstrated significant antibacterial syn-
ergy activities of DhL on P. aeruginosa.
Elastase A and elastase B (LasB) are effectors of Type
II secretion system in P. aeruginosa and are major virulent
factors in lung infection, often related to high death rate in
acute pneumonia [42]. The elastase properties of LasA and
protease activity of LasB play a major role in P. aeruginosa
pathogenesis [43, 44]. LasB secretion is a prominent virulence
factor in cystic fibrosis lung infection [45], which is known
to degrade elastin and collagen in host [46]. To investigate
the effect of DhL on LasA and LasB activities, P. aeruginosa
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Table 3: FICa: MIC of the combination/MICa alone. FICb: MIC of the combination/MICb alone. FICI: FICa + FICb. FICI interpretation:
synergistic effect when FICI ≤ 0.5, additive effect when 1 > FICI < 0.5, and antagonistic effect when FICI > 1.
Microorganism MIC (𝜇g/mL) Chloramphenicol FICa FICb FICI Effect
Pseudomonas aeruginosa PAO1 >400 0.25 ≤0.03 ≤0.28 Synergistic
strain PAO1 was incubated with DhL at 0.12mg/mL (MIC
50
)
as described in Section 2. PAO1 cultural supernatant showed
an exponentially increasing staphylolytic effect indicating
protease activity when compared to S. aureus concentration
in LB as a control (Figure 3(a)). A significant decrease (89 ±
3%) in LasA activity (Figure 3(a)) was observed after 60min
of incubation of S. aureus substrate along with the DhL
treated P. aeruginosa strain PAO1. Furthermore, significant
decrease of 75 ± 5% in LasB activity was also observed when
PAO1 was grown in the presence of DhL (Figure 3(b)). In
parallel control studies, DhL along with S. aureus in absence
of PAO1 did not show any LasA activity as well as DhL and LB
alone did not show elastase activity (data not shown). In both
experiments, PAO1 cultures grown in presence or absence of
DhL were normalized so that the total number of bacteria
remained the same.
LasR is a transcription regulator of LasA and LasB gene
[43, 47]. The mRNA expression level of LasR in PAO1 popu-
lation from mid log phase reduced fivefold after DhL treat-
ment (Figure 3(c)). These results indicated DhL effectively
inhibited both LasA and LasB activity in PAO1 population
by controlling transcription regulator in live bacteria, and
the absence of such virulent activities was not due to loss of
bacterial viability.
P. aeruginosa has the ability to form biofilms, in which
cells are organizedinto layers and enmeshed in a matrix
of mucoid polysaccharides [48]. P. aeruginosa biofilms are
linked to quorum sensing behavior [48, 49] by using two
distinct acyl-homoserine lactone [3]. Biofilm-grown bacte-
rial cells show increased resistance to antibiotics [48]. To
determine whether DhL could prevent biofilm formation,
P. aeruginosa strain PAO1 was incubated in the absence or
in the presence of DhL and then the generation of biofilms
was quantified as described in Section 2. Results indicated a
significant decrease of 55±5% in biofilm formation (Figure 4)
in DhL treated PAO1 compared to the control, suggesting an
inhibitory effect of DhL on P. aeruginosa biofilm formation.
T3S system is a complex multiprotein apparatus that
facilitates the secretion and translocation of effector proteins
such as ExoS, ExoT, ExoU, and ExoY from the cytoplasm of
bacterial cell to the cytoplasm of mammalian cells. Active
T3S system is significantly associated with acute infections,
extreme clinical outcomes, anddeath in patients infectedwith
P. aeruginosa [50]. ExoS and ExoT are bifunctional proteins
with Rho-GAP and ADP-ribosylation activity whereas ExoU
is a potent phosphor lipase and ExoY is adenylate cyclase [9].
In animal infection models mimicking P. aeruginosa medi-
ated acute human infections, such as burn wounds, acute
pneumonia, and corneal infection, it was shown that T3S is
an important virulence mechanism [51, 52]. To determine
whether DhL inhibits the T3S system-mediated secretion of
effector proteins such as ExoS, P. aeruginosa strain PAO1
was incubated in the absence or in the presence of DhL
under T3S system-inducing conditions (see Section 2). The
secreted effectors were analyzed on SDS-PAGE as described
in Section 2. DhL inhibited the secretion of ExoS in PAO1 by
at least 95% (Figure 5 (top panel)). To further confirm this
result, presence of ExoS was screened in the secretion profile
of PA103ΔUΔT: HA-ExoS strain, carrying HA-tagged ExoS,
in the absence or in the presence ofDhL.The secretion ofHA-
tagged ExoS was probed with immunoblotting using specific
anti-HA antibody. These results indicated that DhL blocked
the secretion of HA-ExoS (Figure 5 (bottom panel)).
Several Studies have suggested that T3S system effec-
tors from P. aeruginosa are responsible for inducing rapid
apoptosis in macrophage cells and epithelial cells [49]. In
an effort to support our previous observation, antimicrobial
activity of DhL was tested in a cellular activity assay for
T3S system effector translocation into mammalian cells [53].
P. aeruginosa PAO1 strain was added to J774-Eclone cell
monolayer at MOI of 20 : 1 in the absence or in the presence
of DhL as described in Section 2. After 2 hr of incubation
at 37∘C, cells were stained with Hoechst stain and apoptotic
nuclei were observed under fluorescent microscope. The
total percentage of apoptotic cell counted suggests that DhL
treated P. aeruginosa PAO1 strain fails to induce apoptosis
significantly when compared to untreated PAO1 induced
apoptosis (control). Almost 87 ± 5% inhibition of apoptosis
was observed in PAO1 population previously treated with
DhL (Figure 6). As a positive control of apoptosis we have
treated J774-Eclone cells with Staurosporine (see Section 2).
Together, these results demonstrate that DhL suppresses the
T3S system-mediated secretion of effectors fromPAO1 as well
as the translocation of effectors into the target mammalian
cells.
4. Discussion
P. aeruginosa represents a wide number of strains with
strong pathogenic capacity and has developed a number of
strategies to affect and invade the host cell. PAO1 strain of
P. aeruginosa is the standard laboratory strain as well as
genetic reference strain [33]. PA14, a “multihost” pathogen,
is capable of infecting animals (in a burned mouse model),
plants, insects, and nematodes [54]. Both strains were able
to initiate and maintain chronic infection in rat lung model
[55]. Exotoxin-Uproducing strain, PA103, is a cytotoxic strain
of P. aeruginosa, which is known to cause severe alveolar
epithelial injury during infection [56]. In this study, we have
demonstrated that DhL is bacteriostatic for virulent strains
of Pseudomonas aeruginosa, PA14, and CDN118 [57, 58] but
bacteriocidal for less virulent strains PAO1 and PA103 of P.
aeruginosa.
BioMed Research International 7
PAO1
∗∗∗∗∗
PAO1 + DhL
0
0.2
0.4
0.6
0.8
1.0
1.2
La
sA
 p
ro
te
as
e c
on
ce
nt
ra
tio
n
5 10 20 30 40 50 600
Time (min)
LB + S. aureus
(%
 o
f c
on
tro
l)
(a)
∗
PAO1 PAO1 + DhL
0
0.05
0.1
0.15
0.2
0.25
(O
D
4
9
5
)
El
as
to
ly
tic
 ac
tiv
ity
 
(b)
PAO1
∗
PAO1 + DhL
−8
−6
−4
−2
0
2
4
6
8
10
12
Re
la
tiv
e u
ni
ts 
(fo
ld
 ch
an
ge
)
(c)
Figure 3: Effect of DhL on P. aeruginosa strain PAO1 protease activities. Staphylolytic LasA and elastolytic LasB activities were monitored in
the absence or in the presence of DhL (0.12mg/mL). (a) To measure the proteolytic activity of LasA within the supernatant fraction of the
PAO1 growth culture, a staphylolytic assay was employed accounting the lysis of heat inactivated intact S. aureus at OD
595
as described in
Section 2. Proteolytic activity of PAO1 supernatant (PAO1, ◻) was significantly (asterisk indicates 𝑃 < 0.05) inhibited when PAO1 were treated
with DhL (PAO1 + DhL, e). LB + S. aureus was used as control (I). Data represent the mean of three independent experiments ± SEM. (b)
Levels of LasB elastolytic activity (within the PAO1 cultural supernatant with or without DhL treatment) were measured by Elastin Congo
red assay at OD
495
as described in Section 2. PAO1 were grown in LB broth at 37∘C for 16 hr. The cultures were adjusted to an OD
540
of 3.5–
4.0 before harvesting to eliminate growth-related variations in elastolytic activity. Significant (asterisk indicated 𝑃 < 0.05) decrease in LasB
activity was observed in PAO1 when treated with DhL. Data represent themean of three independent experiments± SEM. (c) Relative mRNA
expression level of LasR gene at mid log phase from DhL treated P. aeruginosa shows fivefold inhibition compared to untreated population.
Data represent the mean of three independent experiments ± SEM.
When PAO1 strainwas treatedwith sub-MICdose ofDhL
(MIC
50
= 0.12mg/mL) and inoculated in growth medium,
a significantly reduced (50 ± 5%) generation time was
observed. Such treatment also modified the susceptibility of
P. aeruginosa toward potent antibiotics and lowered the MIC
systemic antibiotics. A combination of sub-MIC levels of
DhL and antibiotics can help reduce undesirable side effects
from routine antibiotic dosage. The FICI assay of DhL with
conventional antibiotic on PAO1 strain showed significant
synergistic effect.
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Figure 4: Effect of DhL on P. aeruginosa biofilm formation. Over-
night cultures of PAO1 were resuspended in fresh AB medium
(control) and inABmedium supplementedwithDhL (see Section 2)
in PVC tubes. After 24 hr of incubation at 30∘C, the biofilms on the
wall of the tubes were visualized by staining with a crystal violet
solution. Biofilm formation was quantified by measuring OD
546
of
crystal violet-stained wells rinsed with ethanol. Each column is
the mean of three individual experiments with two replicates per
treatment. Significant (asterisk indicated 𝑃 < 0.05) decrease in
biofilm formation was observed in PAO1 when treated with DhL.
Data represent the mean of three independent experiments ± SEM.
DhL treatment also inhibited severalvirulence factors in
PAO1 at the threshold dose of 0.12mg/mL. PAO1 cultural
supernatant treated with DhL showed 89 ± 3% decrease in
LasA activity and 75 ± 5% reduction in LasB activity. Signifi-
cantly low mRNA expression of transcription regulator LasR
corroborates with the activity status as well. It is important
to note that the virulence mechanisms in P. aeruginosa are
highly controlled by transcription factors and regulators. It is
well documented that LasA and LasB transcription activation
requires LasR gene products [33].
DhL treated PAO1 culture failed to demonstrate success-
ful initial attachment phase during the course of biofilm
formation and prolonged observations revealed disruption in
biofilm formation compared to untreated PAO1 culture (data
not shown). Inhibitory effects ofDhLwere also poignant forP.
aeruginosa T3S system that successfully restrained secretion
of important T3S effectors such as ExoS, ExoT, ExoY, and
ExoU.Overall, the results indicated a prominent regulation of
P. aeruginosa growth and virulence due to DhL treatment in
vitro. Finally, when DhL treated P. aeruginosa was cocultured
with mouse macrophage cells, the typical PAO1 induced
cellular apoptosis was successfully controlled, reinforcing the
active inhibition of T3S system virulence which otherwise
leads to cytotoxicity.
Although the exactmechanismofDhLmediated suppres-
sion of P. aeruginosa virulenceis still under investigation, it
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Figure 5: Effect of DhL on Type III secretion. Top panel represents
Type III secretion profile of P. aeruginosa strain PAO1 in presence
of DhL as observed with SDS-PAGE stained with Coomassie blue
stain. Type III null mutant (PA103 ΔUT) was used as a control. Lane
1 represents untreated PAO1 secretion profile and lane 2 represents
treated PAO1 secretion profile. Under Coomassie blue stain, protein
bands were observed at ∼53 kDa, ∼49 kDa, and ∼37 kDa, indicating
ExoT, ExoS, and ExoY, respectively, in PAO1 Type III secretion assay,
which were not shown in DhL treated PAO1 Type III secretion assay.
Lanes 3 and 4 showing untreated and DhL treated control strain
(PA103 ΔUΔT) with no visible Type III secretion profile. Bottom
panel represents immunoblot results of DhL treated PA103ΔUΔT:
HA-ExoS strain carrying HA-tagged ExoS as described in Section 2.
HA specific antibody was used in immunoblot (IB) to confirm the
presence of ∼49KDa ExoS secretion. Experiments were repeated
three times to confirm the observation.
is likely that DhL imparts a direct effect within the bacterial
cells rather than extracellular substances and mucoid layers
of biofilm. Previous studies suggested that the 𝛼-methylene-
𝛾-lactone moiety in sesquiterpene lactones like DhL exerts
its biological activities by Michael-type additions attacking
nucleophiles.Themodified nucleophiles react reversibly with
sulfhydryl groups in the cell such as transcription factors [59,
60]. To confirm the functional properties of DhL, we utilized
a DhL derivative, which is a mixture of two epimers (11S)DH-
DhL and (11R)DH-DhL [21]. DH-DhL epimers which are
devoid of the highly reactive 𝛼-methylene-𝛾-lactone moiety
failed to show any significant antipseudomonalactivity at
similar concentration to DhL (0.24mg/mL).
Due to high mutation rate in bacterial genome, P. aer-
uginosa is extremely difficult to eradicate from mucoid
colonies [61].Therefore, alternatively antivirulence therapy to
prevent P. aeruginosa invasion holds strong grounds against
development of bacterial resistance [15, 62]. The success of
DhL against several virulence effects of P. aeruginosa in this
study can lead to new treatment strategies and could also pave
theway to the reduction of the amount of antibiotics required.
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Figure 6: Effect of DhL on P. aeruginosa induced apoptosis. J774-
Eclone cells were plated in monolayer (5 × 105 cells per well); once
adhered they were infected with PAO1 bacteria previously grown
in LB-DhL (MIC
50
, 0.12mg/mL) or only LB, at a multiplicity of
infection of 20, and incubated for 2 hr at 37∘C in a 5%CO
2
incubator.
In a parallel experiment an equal number of J774-Eclone cells was
subjected to 1 𝜇M Staurosporine for positive control. Cells were
then washed with PBS, stained with Hoechst dye, and subjected
to fluorescence microscopy (Section 2). Five fields were randomly
sampled from each experimental population, and all of the cells
stained with Hoechst dye in each field were counted up to 500
in total. The total number of apoptotic cells with condensed or
fragmented nuclei was determined in the five sampled regions
and was expressed as follows: percentage of apoptosis per sample:
number of apoptotic cells/total number of cells × 100. Each column
is the mean of three individual experiments with two replicates
per treatment. Significant (asterisk indicates 𝑃 < 0.05) decrease
in apoptotic cells was noticed when infected with PAO1 grown in
presence of DhL. Data represent the mean of three independent
experiments ± SEM.
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